There is a long history of talcum powder cancer research. Take a look
at the timeline below to see how long talc has been under the microscope.
Johnson & Johnson announces that the company will no longer sell talc-based powders in North America.
In addressing more than 17,000 pending legal claims, a New Jersey federal court finds scientific evidence of a talc-ovarian cancer connection to be “reliable.”
The FDA holds daylong public hearing on recommendations to expand the definitions of carcinogenic talc and requiring more sensitive testing of talc products.
Johnson & Johnson recalls more than 30,000 bottles of its baby powder after FDA discovered cancer-causing chrysotile asbestos in the product.
The Reuters news service publishes a special report documenting that, in the face of declining baby powder sales, Johnson & Johnson has created marketing campaigns targeting minority populations despite the company’s knowledge of the dangers of talcum powder.
A U.S. House subcommittee held an investigative hearing on the science and safety of talc-based products, prompted by the FDA’s discovery of asbestos-containing talcum powder in certain cosmetics marketed to children and teens. The panel may recommend granting the FDA more authority to mandate safety recalls of cosmetics, powders and personal care products.
The Reuters news service and The New York Times each publish reports, based on corporate and legal documents, stating that Johnson & Johnson was aware of the presence of asbestos in its talcum powder products for decades, but chose to deny the dangers to regulators and the public.
A St. Louis jury finds Johnson & Johnson and its talc supplier liable for more than $4.6 billion in damages on behalf of 22 ovarian cancer victims, finding that the companies were aware of and responsible for cancer-causing asbestos in talcum powder products.
Separate trials in Missouri and California find that J&J’s talcum powder products caused the ovarian cancer of two women, with a combined jury award of more than $525 million.
Baby powder manufacturers begin putting ovarian cancer warning labels on private label products, including those sold at Walmart and Dollar Tree stores.
In three separate trials, juries return verdicts totaling almost $200 million on behalf of women who died of ovarian cancer from using talcum powder for feminine hygiene for decades.
Cramer study: Finds genital talc use associated with factors such as age, weight, race in dramatic increase of ovarian cancer risk.
National Cancer Institute issues report citing talc use as a risk factor for ovarian cancer.
National Institutes of Health Study: Meta-analysis that looked at 30 years of data found significant link between genital talc use and ovarian cancer.
Safe Cosmetic Act in California lists talc as a suspected carcinogen.
Cramer Study – Menopausal Medicine: 10-year case-control study finds women with long-term genital talc use had a two-thirds increase of developing ovarian cancer as a result.
Major talc suppliers place toxicity warning on shipments of talc to manufacturers.
Condom industry removes talc from all products due to ovarian cancer concerns.
Federal National Toxicology Program issues report finding “clear evidence of carcinogenic activity of talc” in rodent-based study.
Cramer Study: First case-control study to link genital talc use with ovarian cancer finds women have a 92% increased risk of ovarian cancer when using talc for feminine hygiene purposes.
Faced with possible federal ban of cosmetic talcum powder, J&J begins testing baby powder with corn starch as a replacement.
Internal J&J memo acknowledges problematic link between genital talc use and ovarian cancer.
British Journal of Obstetrics & Gynecology study discovers talc particles in 75% of ovarian tumors.
First accounts of harmful effects of talc on humans recorded.
Anybody who denies [the published research] risks that the talc industry will be perceived by the public like it perceives the cigarette industry: denying the obvious in the face of all evidence to the contrary.– Alfred P. Wehner J&J toxicology consultant to J&J executives, 1997